Dr. Read's recent research has involved small clinical trials of novel therapeutic approaches for solid tumors. At Emory, he hopes to help develop new treatments for brain tumors and sarcomas.
Titles and Roles
- Associate Professor, Department of Hematology and Medical Oncology
- Emory University School of Medicine
- Research Program
- Discovery and Developmental Therapeutics
William Read, MD, is a medical oncologist who cares for patients with gynecologic malignancies, brain tumors, sarcomas of soft tissue and bone and complicated skin cancers at Winship Cancer Institute of Emory University.
Dr. Read is an associate member of the Discovery and Developmental Therapeutics research program at Winship Cancer Institute. He holds memberships with the International Transplant Skin Cancer Collaborative (ITSCC) and the American Society of Clinical Oncology (ASCO).
Dr. Read earned his undergraduate degree at Carleton College and received his medical degree at the University of Nebraska Medical Center, College of Medicine in Omaha, Nebraska. He completed a residency in internal medicine and fellowship in Hematology and medical oncology at Washington University School of Medicine in St. Louis, Missouri.
Dr. Read is the recipient of the following awards:
- ASCO Career Development Award: "A Phase I/II Study of Bioimmunotherapy with Gefitinib and Pegylated Interferon [alpha]-2a for Patients with Unresectable/ metastatic Squamous Cell Carcinoma of the Skin", 2005
- Methods in Clinical Cancer Research Workshop. American Association for Cancer Research/American Society of Clinical Oncology, 2002
- Megan Wren Award for Excellence in Primary Care, Washington University School of Medicine, St Louis, MO, 1999
- Post-Sophomore Fellowship in Laboratory in Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN, 1993
- David John Field Prize for Energetic Creativity and Humor, Carleton College, Northfield, MN, 1991
Dr. Read's recent research has involved small clinical trials of novel therapeutic approaches for solid tumors. At Emory, he hopes to help develop new treatments for brain tumors and gynecologic malignancies. Additionally, he is interested in interventions to improve quality of life.